A Phase I/II Trial of IO102 and Pembrolizumab With/Without Chemotherapy as First-line Treatment of Metastatic NSCLC

Simple item page
dc.contributor.authorProvencio, M.
dc.contributor.authorSpicer, J.
dc.contributor.authorGarrido, P.
dc.contributor.authorTrigo Perez, J. M.
dc.contributor.authorViteri, S.
dc.contributor.authorBosch-Barrera, J.
dc.contributor.authorInsa, A.
dc.contributor.authorFelip, E.
dc.contributor.authorDe Castro Carpeno, J.
dc.contributor.authorCoart, E.
dc.contributor.authorSchmidt, E.
dc.contributor.authorChristiansen, A.
dc.contributor.authorAndersen, M. Hald
dc.contributor.authorZocca, M.
dc.contributor.authorEhrnrooth, E.
dc.contributor.authorPaz-Aras, L.
dc.contributor.authoraffiliation[Provencio, M.] Hosp Puerta de Hierro Majadahonda, Madrid, Spain
dc.contributor.authoraffiliation[Spicer, J.] Kings Coll London, Guys Hosp, London, England
dc.contributor.authoraffiliation[Garrido, P.] Hosp Univ Ramon & Cajal, Madrid, Spain
dc.contributor.authoraffiliation[Trigo Perez, J. M.] Hosp Univ Virgen de La Victoria, Inst Invest Biomed Malaga Ibima, Malaga, Spain
dc.contributor.authoraffiliation[Viteri, S.] Hosp Univ Quiron Dexeus, Inst Oncol Dr Rosell, Grp Quironsalud, Barcelona, Spain
dc.contributor.authoraffiliation[Bosch-Barrera, J.] Hosp Univ Girona Doctor Josep Trueta, Catalan Inst Oncol, Girona, Spain
dc.contributor.authoraffiliation[Insa, A.] Hosp Clin Univ, Clin Fdn Incliva, Valencia, Spain
dc.contributor.authoraffiliation[Felip, E.] Vall DHebron Inst Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[De Castro Carpeno, J.] Hosp Univ Hm Sanchinarro, Ctr Integral Oncol Clara Campal, Madrid, Spain
dc.contributor.authoraffiliation[Coart, E.] Iddi, Brabant Wallon, Belgium
dc.contributor.authoraffiliation[Schmidt, E.] Merck & Co Inc, Kenilworth, NJ USA
dc.contributor.authoraffiliation[Christiansen, A.] Io Biotech, Copenhagen, Denmark
dc.contributor.authoraffiliation[Andersen, M. Hald] Io Biotech, Copenhagen, Denmark
dc.contributor.authoraffiliation[Zocca, M.] Io Biotech, Copenhagen, Denmark
dc.contributor.authoraffiliation[Ehrnrooth, E.] Io Biotech, Copenhagen, Denmark
dc.contributor.authoraffiliation[Paz-Aras, L.] Hosp Univ 12 Octubre, Madrid, Spain
dc.date.accessioned2025-01-07T15:11:33Z
dc.date.available2025-01-07T15:11:33Z
dc.date.issued2019-10-01
dc.identifier.doi10.1016/j.jtho.2019.08.1356
dc.identifier.essn1556-1380
dc.identifier.issn1556-0864
dc.identifier.unpaywallURLhttp://www.jto.org/article/S1556086419320398/pdf
dc.identifier.urihttps://hdl.handle.net/10668/26948
dc.identifier.wosID492162203271
dc.issue.number10
dc.issue.numberS
dc.journal.titleJournal of thoracic oncology
dc.journal.titleabbreviationJ. thorac. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.numberS643-S643
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.subjectNSCLC
dc.subjectVaccine
dc.subjectPembrolizumab
dc.titleA Phase I/II Trial of IO102 and Pembrolizumab With/Without Chemotherapy as First-line Treatment of Metastatic NSCLC
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number14
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía